Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Clin Exp Dermatol ; 2024 Mar 02.
Article in English | MEDLINE | ID: mdl-38430106

ABSTRACT

BACKGROUND: Bullous Pemphigoid (BP) is the most common autoimmune blistering disease. Most patients are elderly and associate multiple comorbidities. Topical and systemic corticosteroids are considered as the first-line treatment for BP and immunosuppressors are used as steroid-sparing treatments but both have side effects and contraindications which are even more common in this elderly population. New treatments targeting interleukins and receptors related to BP pathogenesis have been proposed to decrease this side effects while achieving equal or better effectiveness response rates.Omalizumab is a monoclonal antibody that targets IgE that has been proposed for the treatment of BP due to the evidence that IgE autoantibodies play an essential role in BP pathogenesis. OBJECTIVES AND METHODOLOGY: To assess the efficacy and security of Omalizumab for the treatment of BP, we carried out a multicenter, retrospective, observational study including patients diagnosed of BP who received omalizumab for at least 3 months from 15 tertiary hospitals in Spain. IgE levels prior to treatment was measured and we evaluate the possible correlation with clinical response. We excluded patients treated with Omalizumab for less than 3 months as we consider this duration is insufficient for a comprehensive assessment of its efficacy. To evaluate the effectiveness of the treatment we used the percentage of BSA improvement. RESULTS: We included 36 patients. The vast majority associate multiple comorbidities and all patients had used other systemic therapies apart from corticoids before Omalizumab.83% experienced some kind of treatment response and 42% of all patient treated achieved complete response.We did not find any correlation between higher levels and a better response (p=0,1791).All patients tolerated Omalizumab without reported side-effects. CONCLUSIONS: Omalizumab is a good therapeutic alternative for BP as it obtained clinical response in most patients and nearly half of the cases achieving complete response. It showed no side effects which is crucial in elderly patients suffering from BP.

3.
J Am Acad Dermatol ; 89(1): e41-e42, 2023 Jul.
Article in English | MEDLINE | ID: mdl-33878405

Subject(s)
Tourniquets , Humans
5.
Pediatr Dermatol ; 40(1): 224-225, 2023 Jan.
Article in English | MEDLINE | ID: mdl-36178261

ABSTRACT

Diaper dermatitis is a common dermatosis that usually responds to adequate hygiene and topical treatment, but can be a therapeutic challenge. Continuous exposure to feces and urine can cause extensive erosions and pain. The use of hydrocolloid dressings may be helpful in keeping the skin isolated from stool and urine, reducing pain, and enabling skin lesions to heal. We explain an easy technique, utilizing stoma powder and a hydrocolloid dressing, for parents to apply at home.


Subject(s)
Bandages, Hydrocolloid , Diaper Rash , Humans , Bandages, Hydrocolloid/adverse effects , Diaper Rash/therapy , Diaper Rash/etiology , Skin , Wound Healing , Administration, Topical
9.
Pediatr Dermatol ; 37(5): 872-876, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32598043

ABSTRACT

Congenital hemangiomas (CH) are benign vascular tumors that are present at birth and do not stain for the marker Glut-1. Herein, we describe five cases of CH with atypical presentations: 3 with late growth, 1 with slow involution, and 1 that partially involuted rapidly then manifested late growth.


Subject(s)
Hemangioma , Skin Neoplasms , Vascular Neoplasms , Coloring Agents , Hemangioma/diagnosis , Humans , Infant , Infant, Newborn , Phenotype , Skin Neoplasms/diagnosis
15.
Photodermatol Photoimmunol Photomed ; 35(1): 54-56, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30007081

ABSTRACT

Mycosis Fungoides is the most common cutaneous T-cell lymphoma however, it is rare in children. We present the case of a Folliculotropic Mycosis Fungoides in a 13-year-old boy which initially presented as a plaque on his face and was treated with local PUVA therapy. Afterwards the lesions spread so the treatment was changed to systemic PUVA with good response. Although the experience in the treatment of Mycosis Fungoides in pediatric patients is limited, PUVA therapy seems to be an effective and safe option.


Subject(s)
Ficusin/administration & dosage , Mycosis Fungoides/drug therapy , PUVA Therapy , Skin Neoplasms/drug therapy , Ultraviolet Rays , Adolescent , Humans , Male , Mycosis Fungoides/pathology , Skin Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...